Effects of a Psychedelic, Tropical Tea, Ayahuasca, on the Electroencephalographic (EEG) Activity of the Human Brain during a Shamanistic Ritual Erik Hoffmann, Jan M. Keppel Hesselink, Yatra-W.M. da Silveira Barbosa MAPS Bulletin, Multidisciplinary Association for Psychedelic Studies, USA, Spring 2001, pp 25-30 Abstract Eight channels of EEG from 12 volunteers participating in a workshop in Brazil were recorded under field conditions before and after a shamanistic ritual in which the psychoactive tea, ayahuasca, was consumed. Following three doses of the tea, the subjects showed strong and statistically significant increases of both EEG alpha (8-13Hz) and theta (4-8Hz) mean amplitudes compared to baseline while beta [...]
Lire la suiteOral Cannabidiol Does Not Convert to Δ8-THC or Δ9-THC in Humans : A Pharmacokinetic Study in Healthy Subjects Jose´ Alexandre S. Crippa, Antonio Waldo Zuardi, Jaime Eduardo Cecılio Hallak, Bruna Miyazawa, Sandra Aparecido Bernardo, Carmem Maria Donaduzzi, Silvane Guzzi, Wagner Alex Jann Favreto, Alline Campos, Maria Eugenia C. Queiroz, Francisco S. Guimaraes, Patrıcia Moura da Rosa Zimmermann, Letıcia Mello Rechia, Volnei Jose Tondo Filho, and Liberato Brum Junior Cannabis and Cannabinoid Research, 2019, Volume X, Number X DOI: 10.1089/can.2019.0024 Abstract Introduction: Recent studies have suggested that cannabidiol (CBD) could interconvert into Delta-8- and Delta-9- tetrahydrocannabinol. Materials and Methods: Thus, we tested the plasma samples of 120 healthy [...]
Lire la suiteReceptor-Enriched Analysis of functional connectivity by targets (REACT) : A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA Ottavia Dipasquale, Pierluigi Selvaggi, Mattia Veronese, Anthony S. Gabay, Federico Turkheimer, Mitul A. Mehta NeuroImage, 2019, 195, 252–260 https://doi.org/10.1016/j.neuroimage.2019.04.007 A B S T R A C T One of the main limitations of pharmacological fMRI is its inability to provide a molecular insight into the main effect of compounds, leaving an open question about the relationship between drug effects and haemodynamic response. The aim of this study is to investigate the acute effects of 3,4-methylene-dioxymethamphetamine (MDMA) on functional [...]
Lire la suiteScientists mass-produce 'magic mushroom' active ingredient from bacteria The study shows that psilocybin can be produced in a sustainable manner. https://www.zmescience.com/medicine/scientists-mass-produce-magic-mushroom-active-ingredient-from-bacteria/ byTibi Puiu October 3, 2019 Psilocybin, the active psychoactive compound found in specific mushrooms, is a promising drug that can be used to treat depression, anxiety, addiction, and post-traumatic stress disorder. Looking towards the future, researchers at Miami University have used genetic engineering to coax harmless E. coli bacteria to produce psilocybin. Psilocybe semilanceata. Credit: Pixabay. The mushrooms that produce psilocybin, such as Psilocybe cubensis, are not particularly expensive or difficult to grow. However, they do take up a lot of space and require many [...]
Lire la suiteCannabinoids, Endocannabinoids and Cancer Daniel J. Hermanson and Lawrence J. Marnett Cancer Metastasis Reviews, 2011, 30, (3-4), 599–612. doi:10.1007/s10555-011-9318-8. 1. Introduction 1.1 Cannabinoid Function Endocannabinoids are bioactive lipids that have a range of interesting activities mediated by two G-protein-coupled receptors (CB1 and CB2) and other putative targets [1-3]. The CB1 receptor is present in the central nervous system and mediates the psychotropic effects of exogenous cannabinoids such as Δ9-tetrahydrocannabinol (THC), the active component of marijuana. In the brain, endocannabinoids and cannabinoids combine with CB1 cannabinoid receptors on axon terminals and regulate ion channel activity and neurotransmitter release [4]. Binding to the CB1 receptor is responsible for [...]
Lire la suiteLegal highs : staying on top of the flood of novel psychoactive substances David Baumeister, Luis M. Tojo and Derek K. Tracy Therapeutic Advances in Psychopharmacology, 2015, Vol. 5, (2), 97–132 DOI: 10.1177/2045125314559539 Abstract : There has been growing clinical, public, and media awareness and concern about the availability and potential harmfulness of so-called ‘legal highs’, which are more appropriately called new or novel psychoactive substances (NPS). A cat-and-mouse process has emerged wherein unknown chemists and laboratories are producing new, and as yet nonproscribed, compounds for human consumption; and as soon as they are banned, which they inevitably are, slightly modified analogues are produced to [...]
Lire la suitePsychedelics David E. Nichols Pharmacological Review, 2016, 68, 264–355 http://dx.doi.org/10.1124/pr.115.011478 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . .266 I. Introduction . . . . . . . . . . . . . . . . . . . . . . . [...]
Lire la suiteCould Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy ? Chung Mo Koo, Hoon-Chul Kang Journal of Epilepsy Research, 2017, 7, 16-20. pISSN 2233-6249 / eISSN 2233-6257 www.kes.or.kr Epilepsy is an important disease that affects brain function, particularly in those under 3 years old. Uncontrolled seizures can affect cognitive function and quality of life. For these reasons, many trials have been conducted to investigate treatments for pediatric epilepsy. Currently, many antiepileptic drugs are available for the treatment of epilepsy, but cases of intractable epilepsy continue to exist. In the past, cannabis has been tested as a potential treatment of intractable epilepsy. Since [...]
Lire la suiteDon’t Fear the Reefer—Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy - Commentary M. Scott Perry Epilepsy Currents, 2019, Vol. 19, (2), 93-95 DOI: 10.1177/1535759719835671 Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome Devinsky O, Patel AD, Cross JH, et al; GWPCARE3 Study Group. N Engl J Med, 2018, 378, 1888-1897. Background : Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with the Lennox-Gastaut syndrome, a severe developmental epileptic encephalopathy. Methods : In this double-blind, placebo-controlled trial conducted [...]
Lire la suiteDosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study Richard J. Huntsman, Richard Tang-Wai, Jane Alcorn, Stephanie Vuong, Bryan Acton1,5, Scott Corley, Robert Laprairie, Andrew W. Lyon, Simona Meier, Darrell D. Mousseau, Doris Newmeyer, Erin Prosser-Loose, Blair Seifert, Jose Tellez-Zenteno, Linda Huh, Edward Leung and Philippe Major Frontiers in Neurology, 2019, 10:716. doi: 10.3389/fneur.2019.00716 Purpose : There is uncertainty regarding the appropriate dose of Cannabidiol (CBD) for childhood epilepsy. We present the preliminary data of seven participants from the Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E) study. Methods : The study is an open-label, [...]
Lire la suite